Project Grant R21HL177773
Award Date
1/15/25
Completion Date
12/31/26
Dollars Obligated
$153K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
This $1,147,992 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to advance precision medicine for acute respiratory distress syndrome (ARDS) and sepsis. The award aims to address key unanswered questions about the functional immune response and pathogen drivers underlying distinct "hyperinflammatory" and "hypoinflammatory" phenotypes observed in these critical...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $200,502 to the Regents of the University of California, San Francisco (UCSF) for a 5-year research study. The study aims to identify metabolite and protein drivers of Acute Respiratory Distress Syndrome (ARDS) evolution in patients with hyper- and hypo-inflammatory ARDS subtypes. The research will utilize comprehensive metabolic...
This $165,856 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 Cardiovascular Diseases Research program will fund a study to characterize current practice patterns and outcomes associated with corticosteroid therapy for acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) in critically ill patients. The study will analyze a large national cohort to 1) document corticosteroid dosing, route, timing, and duration for managing AE-IPF, and 2)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), totals $827,682 and is effective from July 29, 2024 through June 30, 2029. The award aims to develop comprehensive imaging approaches to characterize lung perfusion and guide treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition that is a leading cause of death from COVID-19. The project will leverage...
This $688,163 federal Project Grant award was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The grant supports research at the University of Pittsburgh focused on investigating indole metabolites as novel danger signals that can drive acute lung injury and the development of acute respiratory distress syndrome (ARDS). Key objectives of the 4-year research project include determining the mechanisms by which indole...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $704,795 to Baylor College of Medicine to develop a cell-based immunomodulation therapy to suppress lung inflammation and promote repair in Acute Respiratory Distress Syndrome (ARDS). The research aims to engineer retinal pigment epithelial (RPE) cells to produce anti-inflammatory cytokines (IL-1RA, IL-10) for local, sustained delivery to the lungs via airway and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $873,736 to Children's Hospital Los Angeles to conduct research on acute respiratory distress syndrome (ARDS) in children. The key objectives are to: 1) validate the use of the end tidal alveolar dead space fraction (AVDSF) as a marker for mortality risk stratification in pediatric ARDS, 2) determine if AVDSF can identify...
This $775,992 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The grant supports research at the University of North Carolina at Chapel Hill to investigate the role of regulatory T cells (Tregs) and glucocorticoid signaling in resolving acute lung injury and pneumonia. The project aims to determine how Treg glucocorticoid receptor signaling affects Treg function and the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $186,408 to the University of Washington to support research on targeting CD14 as a novel therapeutic approach for acute respiratory distress syndrome (ARDS). The project aims to: Analyze blood leukocyte data to determine the effects of the CD14-blocking monoclonal antibody IC14 on cellular targets in severe COVID-19 patients. Evaluate...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) is funding a randomized clinical trial to investigate the use of corticosteroids for reducing post-extubation aspiration in acute respiratory failure (ARF) survivors. The $257,983 award, spanning from Sep 2024 to Aug 2026, will be used to conduct a multi-center study evaluating whether a short course of intravenous corticosteroids can improve laryngeal edema, swallowing function, and reduce...